GKV Capital Management Co. Inc. Buys New Position in Eli Lilly and Company (NYSE:LLY)

GKV Capital Management Co. Inc. acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 15,462 shares of the company’s stock, valued at approximately $11,937,000. Eli Lilly and Company comprises 4.9% of GKV Capital Management Co. Inc.’s portfolio, making the stock its 4th largest position.

Several other large investors also recently bought and sold shares of LLY. Highline Wealth Partners LLC lifted its position in Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock valued at $35,000 after acquiring an additional 20 shares during the last quarter. FPC Investment Advisory Inc. increased its position in shares of Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after purchasing an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $48,000. Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $50,000. Finally, Fiduciary Advisors Inc. purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $58,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LLY. Morgan Stanley decreased their price objective on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a report on Wednesday, April 9th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Wells Fargo & Company raised their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Finally, Guggenheim reduced their price objective on Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a research note on Monday. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,012.00.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $734.85 on Thursday. The company has a market cap of $696.76 billion, a P/E ratio of 62.75, a PEG ratio of 1.40 and a beta of 0.51. The business has a 50 day moving average of $830.10 and a two-hundred day moving average of $820.95. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.